Macrophage AMPK β1 activation by PF-06409577 reduces the inflammatory response, cholesterol synthesis, and atherosclerosis in mice
Emily A. Day,
Logan K. Townsend,
Sonia Rehal,
Battsetseg Batchuluun,
Dongdong Wang,
Marisa R. Morrow,
Rachel Lu,
Lucie Lundenberg,
Jessie H. Lu,
Eric M. Desjardins,
Tyler K.T. Smith,
Amogelang R. Raphenya,
Andrew G. McArthur,
Morgan D. Fullerton,
Gregory R. Steinberg
Affiliations
Emily A. Day
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, ON, Canada
Logan K. Townsend
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, ON, Canada
Sonia Rehal
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, ON, Canada
Battsetseg Batchuluun
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, ON, Canada
Dongdong Wang
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, ON, Canada
Marisa R. Morrow
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, ON, Canada
Rachel Lu
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, ON, Canada
Lucie Lundenberg
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, ON, Canada
Jessie H. Lu
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, ON, Canada
Eric M. Desjardins
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, ON, Canada
Tyler K.T. Smith
Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, Centre for Infection, Immunity and Inflammation, Ottawa Institute of Systems Biology, Centre for Catalysis Research and Innovation, University of Ottawa, Ottawa, ON, Canada
Amogelang R. Raphenya
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
Andrew G. McArthur
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
Morgan D. Fullerton
Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, Centre for Infection, Immunity and Inflammation, Ottawa Institute of Systems Biology, Centre for Catalysis Research and Innovation, University of Ottawa, Ottawa, ON, Canada
Gregory R. Steinberg
Centre for Metabolism, Obesity and Diabetes Research, Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Endocrinology and Metabolism, Department of Medicine, McMaster University, ON, Canada; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada; Corresponding author
Summary: Atherosclerotic cardiovascular disease is characterized by both chronic low-grade inflammation and dyslipidemia. The AMP-activated protein kinase (AMPK) inhibits cholesterol synthesis and dampens inflammation but whether pharmacological activation reduces atherosclerosis is equivocal. In the current study, we found that the orally bioavailable and highly selective activator of AMPKβ1 complexes, PF-06409577, reduced atherosclerosis in two mouse models in a myeloid-derived AMPKβ1 dependent manner, suggesting a critical role for macrophages. In bone marrow-derived macrophages (BMDMs), PF-06409577 dose dependently activated AMPK as indicated by increased phosphorylation of downstream substrates ULK1 and acetyl-CoA carboxylase (ACC), which are important for autophagy and fatty acid oxidation/de novo lipogenesis, respectively. Treatment of BMDMs with PF-06409577 suppressed fatty acid and cholesterol synthesis and transcripts related to the inflammatory response while increasing transcripts important for autophagy through AMPKβ1. These data indicate that pharmacologically targeting macrophage AMPKβ1 may be a promising strategy for reducing atherosclerosis.
